Endocrinologie et Métabolisme, hôpital Huriez, Institut National de la Santé et de la Recherche Médicale Unité 859, Centre Hospitalier et Universitaire de Lille, 1 rue Polonovski, F-59045 Lille, France.
J Clin Endocrinol Metab. 2012 Nov;97(11):E2078-83. doi: 10.1210/jc.2012-2115. Epub 2012 Sep 20.
For the last 10 yr, continuous glucose monitoring (CGM) has brought up new insights into the accuracy of blood glucose analysis.
Our objective was to determine how islet graft function was able to influence the various components of dysglycemia after islet transplantation (IT).
We conducted a single-arm open-labeled study with a 3-yr follow-up in a referral center (ClinicalTrial.gov identifiers NCT00446264 and NCT01123187).
Twenty-three consecutive patients with type 1 diabetes (14 islet alone, nine islet after kidney) received IT within 3 months using the Edmonton protocol.
INTERVENTION included 72-h CGM before and 3, 6, 9, 12, 24, and 36 months after transplantation.
Graft function was estimated via β-score, a previously validated index (range 0-8) based on treatment requirements, C-peptide, blood glucose, and glycated hemoglobin.
At the 3-yr visit, graft function persisted in 19 patients (82%), and 10 (43%) remained insulin independent. Glycated hemoglobin decreased in the whole cohort from 8.3% (7.3-9.0%) at baseline to 6.7% (5.9-7.7%) at 3 yr [median (interquartile range), P < 0.01]. Mean glucose, glucose sd, and time spent with glycemia above 10 mmol/liter (hyperglycemia) and below 3 mmol/liter (hypoglycemia) were significantly lower after IT (P < 0.05 vs. baseline). The four CGM outcomes were related to β-score (P < 0.001). However, partial function (β-score >3) was sufficient to abrogate hypoglycemia; suboptimal function (β-score >5) was necessary to significantly improve mean glucose, glucose sd, and hyperglycemia; and optimal function (β score >7) was necessary to normalize them.
The four components of dysglycemia were not equally affected by the degree of islet graft function, which could have important implications for future development of β-cell replacement. A β-score above 3 dramatically reduced the occurrence of hypoglycemia.
在过去的 10 年中,连续血糖监测(CGM)为血糖分析的准确性提供了新的见解。
我们的目的是确定胰岛移植物功能如何影响胰岛移植(IT)后各种血糖异常成分。
我们在一个转诊中心进行了一项单臂开放性标记研究,随访时间为 3 年(ClinicalTrials.gov 标识符 NCT00446264 和 NCT01123187)。
23 例 1 型糖尿病患者(14 例胰岛单独,9 例胰岛后肾)接受了 Edmonton 方案的 IT,时间在 3 个月内。
干预措施包括移植前 72 小时 CGM 和移植后 3、6、9、12、24 和 36 个月的 CGM。
β 评分是评估移植物功能的指标,β 评分是基于治疗需求、C 肽、血糖和糖化血红蛋白的一个经过验证的指数(范围 0-8)。
在 3 年的随访中,19 名患者(82%)的移植物功能持续存在,10 名患者(43%)仍保持胰岛素独立性。整个队列的糖化血红蛋白从基线时的 8.3%(7.3-9.0%)下降到 3 年时的 6.7%(5.9-7.7%)[中位数(四分位距),P <0.01]。与基线相比,IT 后平均血糖、血糖标准差和血糖高于 10 mmol/L(高血糖)和低于 3 mmol/L(低血糖)的时间显著降低(P <0.05)。四项 CGM 结果与β评分相关(P <0.001)。然而,部分功能(β评分>3)足以消除低血糖;次优功能(β评分>5)有必要显著改善平均血糖、血糖标准差和高血糖;而最佳功能(β评分>7)则需要使其正常化。
血糖异常的四个成分受胰岛移植物功能程度的影响并不均等,这对未来β细胞替代的发展可能具有重要意义。β 评分大于 3 可显著降低低血糖的发生。